MARKET WIRE NEWS

Weight Watchers Report Finds Integrated GLP-1 Support Drives Significantly Greater Weight Loss Than Medication Alone

MWN-AI** Summary

Weight Watchers has released its GLP-1 Results Report, revealing that members who engaged with the Weight Watchers GLP-1 Success Program experienced significantly greater weight loss than those using medication alone. The report highlights that Med+ members regularly utilizing the program lost up to 61% more weight in the initial month and averaged 29% more weight loss over one year compared to those who relied solely on GLP-1 medications. The data emphasizes that those on Weight Watchers’ program not only achieved better weight loss outcomes but also showed improvements in various health measures, including blood pressure and diet quality.

CEO Tara Comonte notes the transformative role of GLP-1 medications in obesity care, while stressing that successful weight management requires more than just medication. The integrated approach by Weight Watchers, combining medical prescriptions with structured nutritional and behavioral support, allows for enhanced results and sustainability in weight loss efforts.

The GLP-1 Success Program also addresses common issues related to weight loss medications, such as side effects and nutritional needs, thereby helping members maintain muscle mass and achieve a balanced diet. Furthermore, an impressive 72% of participants reported that the program assisted in minimizing GLP-1 side effects, supporting long-term adherence to the treatment.

The evidence reflects that Weight Watchers’ methodology is effective, with a remarkable 75% of members indicating improved confidence and quality of life. With a proven track record of integrated, science-backed weight management solutions, Weight Watchers positions itself as a leader in promoting sustainable health outcomes linked to GLP-1 medications. The findings underscore the importance of combining medical advancements with dedicated lifestyle support for lasting success in weight health.

MWN-AI** Analysis

The recent report from Weight Watchers (NASDAQ: WW) detailing the impact of their GLP-1 Success Program warrants serious consideration for investors looking at the health and wellness sector. This innovative approach—integrating GLP-1 medications with behavioral support and nutritional guidance—has led to significant weight loss results for participants, surpassing outcomes reported by competitors.

Key findings indicate that individuals engaging in the GLP-1 Success Program lost, on average, 61% more weight in the first month compared to those on medication alone. This trend continues with a reported 30% greater weight loss after a year. These results not only highlight the efficacy of combining lifestyle changes with medical treatments, but they also position Weight Watchers as a leader in a burgeoning sector focused on obesity management and metabolic health.

From a market perspective, Weight Watchers is strategically positioned to capitalize on the rising prevalence of obesity and associated health issues. With the World Health Organization emphasizing the importance of holistic approaches to weight management, Weight Watchers' model—which combines medication prescription with lifestyle coaching—stands out. This integrated platform enhances member adherence and promotes sustained weight loss, making it appealing not just to members, but also to healthcare providers and insurers who are increasingly focused on long-term health outcomes.

Moreover, the reported improvements in health indicators such as blood pressure and diet quality further bolster the company’s value proposition. As public health initiatives increasingly focus on supporting healthier lifestyles, Weight Watchers' comprehensive approach could attract a broader customer base, ultimately enhancing revenue potential.

In summary, investors should watch Weight Watchers closely. Their successful integration of medical and lifestyle solutions positions them favorably in a growing market, potentially leading to sustained growth and profitability as the demand for effective obesity management solutions rises.

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.

Source: GlobeNewswire

Weight Watchers’ Med+ members who regularly engaged with their GLP-1 Success Program lost up to 61% more body weight in the first month and 29% more in one year, on average, than those who took medication alone.

Med+ members prescribed medication also reported, on average, over 30% more weight loss than select competitors at 12 months.

NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today released a GLP-1 Results Report which finds that individuals who take GLP-1 medications and regularly engage in the Weight Watchers GLP-1 Success Program achieved significantly greater weight loss and better health outcomes than those using medication alone. The Weight Watchers evidence review builds on a growing body of research on long-term weight management. For example, a recent systematic review published in the British Medical Journal found that weight regain commonly occurs after discontinuation of anti-obesity medications, while guidance from the World Health Organization continues to emphasize the role of nutrition, physical activity, and other lifestyle factors in supporting metabolic health.

“GLP-1 medications are transforming obesity care — but a growing body of research is proving that medication alone is not enough to create lasting results,” said Weight Watchers CEO Tara Comonte. “To maximize the impact of these medical breakthroughs, Weight Watchers has established an integrated weight health platform that combines medication with structured nutritional, behavioral, and lifestyle supports. The results speak for themselves: members who pair weight loss medication with Weight Watchers’ GLP-1 Success Program lose up to 61% more weight in the first month and nearly 30% more weight over a year, on average, compared to those who do not engage with our approach. Clearly, GLP-1s work better with Weight Watchers.”

Weight Watchers’ Med+ platform, combined with the GLP-1 Success Program, offers access to board-certified physicians, FDA-approved prescriptions, and lifestyle support to drive better outcomes and create lasting habits that can sustain results over time. Designed to specifically address side effects, nutrition gaps, muscle loss, and plateaus, the program helps members stay consistent with the tools they need for success throughout their GLP-1 journey.

The GLP-1 Results Report also identified benefits beyond the scale. Additional clinical and real-world evidence cited show that Weight Watchers programs are associated with improvements in important health and behavioral measures — including hemoglobin A1c, blood pressure, diet quality, physical activity, and quality of life — that support long-term health and sustainability.

In the Weight Watchers app, members can track nutrition, follow guided fitness and strength-focused movement sessions, connect with others on GLP-1s, access dietitians, and discover easy recipes and meal plans — supporting sustainable weight loss and maintaining muscle. The membership also offers a variety of workshops led by physicians, registered dietitians, and Weight Watchers-trained coaches to help members maximize the impact of their GLP-1s.

The key findings in the GLP-1 Results Report illustrate:

Clinical and Real-World Findings

  • Weight Watchers Med+ members prescribed GLP-1 medications lost 7.4 pounds in the first four weeks, and reached 21% average weight loss at 12 months and 20.5% average weight loss at 24 months.
  • Among Weight Watchers Med+ members, those who actively engaged with the GLP-1 Success Program lost 61.3% more body weight after just one month compared with members who did not engage in additional support.
    • The advantage continued over time. Weight Watchers Med+ members who regularly engaged with the GLP-1 Success Program consistently lost more weight than those who did not engage in additional support — with improved outcomes observed at 3, 6, and 12 months, underscoring the value of combining medication with structured lifestyle guidance.
  • Weight Watchers Med+ members prescribed GLP-1 medications reported, on average, over 30% more body weight loss than select competitors at 12 months.
  • In one comparative analysis, members achieved 72% greater average weight loss than a cohort receiving compounded GLP-1 medications through Hims & Hers.

Reducing Side Effects and Supporting Sustainability

  • Nearly 72% of members on the Weight Watchers GLP-1 Success Program reported that the program helped minimize GLP-1 side effects, which can support better adherence and long-term success.
  • Among members prescribed obesity medication through the Med+ Program, who began treatment with high blood pressure, 87% had normal blood pressure after 12 months.
  • The GLP-1 Success Program also emphasizes evidence-based nutrition targets like protein, fiber, and hydration, helping to preserve muscle mass, reduce gastrointestinal discomfort, and support adequate nutrient intake during weight loss.

Scalable Impact for the Future of Weight Health

  • 75% of members report improved confidence and quality of life.
  • 71% of members say the program helped them become the healthiest version of themselves.
  • 81% say Weight Watchers has changed their life for the better.

ABOUT WEIGHT WATCHERS
Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has led with science to deliver its members the personalized support they need to reach and sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path forward that is rooted in research, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com.

For media inquiries, please contact:
Lizzy Levitan
WW@hunt-gather.com 

For investor inquiries, please contact:
John Mills or Anna Kate Heller
WeightWatchers@icrinc.com 


FAQ**

How does WW International Inc. WW plan to scale the GLP-1 Success Program to accommodate a growing membership, considering its promising results in weight loss compared to medication alone?

WW International Inc. plans to scale the GLP-1 Success Program by enhancing digital platforms, expanding member support resources, and leveraging data-driven insights to accommodate increasing demand while ensuring effective outcomes in weight loss.

What specific strategies will WW International Inc. WW implement to maintain high engagement levels among Med+ members in the GLP-1 Success Program over the long term?

WW International Inc. will implement personalized coaching, mobile app enhancements, ongoing education about GLP-1 benefits, community support initiatives, and tailored nutritional guidance to maintain high engagement levels among Med+ members in the GLP-1 Success Program.

Given the reported improvements in health measures among Med+ members, how does WW International Inc. WW intend to leverage these findings to enhance its market position against competitors?

WW International Inc. plans to leverage reported health improvements among Med+ members by promoting evidence-based success stories in marketing campaigns, enhancing member engagement through tailored wellness programs, and differentiating its offerings to strengthen its competitive market position.

How does WW International Inc. WW plan to address potential barriers to access for its integrated weight management solutions, particularly for those seeking GLP-1 medications and associated lifestyle support?

WW International Inc. plans to enhance accessibility to its integrated weight management solutions by expanding partnerships with healthcare providers, increasing educational resources on GLP-1 medications, and offering personalized lifestyle support for diverse populations.

**MWN-AI FAQ is based on asking OpenAI questions about WW International Inc. (NASDAQ: WW).

WW International Inc.

NASDAQ: WW

WW Trading

-1.18% G/L:

$22.105 Last:

633,170 Volume:

$22.90 Open:

mwn-ir Ad 300

WW Latest News

WW Stock Data

$241,583,788
9,876,073
0.39%
42
N/A
Personal Services
Consumer Discretionary
US
New York

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App